Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study

PSOGI and BIG RENAPE working groups

研究成果: 雜誌貢獻文章

3 引文 (Scopus)

摘要

Introduction: Peritoneal metastasis (PM) of hepatocellular carcinoma (HCC) without distant spread are rare. The related prognosis is poor without standard treatment available. The role of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly documented. Methods: An international multicentric cohort was constituted by retrospective analysis of 21 patients undergoing CRS/HIPEC for PM of HCC between 1992 and 2016 from 10 reference centers of PSOGI. Data on clinical features, treatment strategies, and survival outcomes were analyzed. Results: The median time interval from the diagnosis of PM to the procedure was 4.5 months. The median peritoneal cancer index was 14. Sixteen patients had complete cytoreduction (CCR0-1). Ten patients had grades 3 to 4 complications. The median duration of follow-up was 52.2 months. The median OS was 46.7 months. The projected 3y-OS and 5y-OS were 88.9 and 49.4% respectively. The median OS for patients with CCR0-1 resection was not reached whereas it was 5.9 months for those with CCR2-3 resection after CRS (p = 0.0005). The median RFS was 26.3 months and projected RFS at 3 years of 36.5 months Three prognostic factors were associated with improved RFS in the univariate analysis: preoperative chemotherapy (p = 0.0156), PCI >15 (p = 0.009), Number of chemotherapy agents used for HIPEC (p = 0.005). Conclusion: CRS/HIPEC is a safe and effective approach in selected patients with PM of HCC. CRS/HIPEC gives the patient a chance for a good relapse free and overall survival and should be considered as an option.

原文英語
頁(從 - 到)1786-1792
頁數7
期刊European Journal of Surgical Oncology
44
發行號11
DOIs
出版狀態已發佈 - 十一月 1 2018

指紋

Multicenter Studies
Hepatocellular Carcinoma
Carcinoma
Drug Therapy
Neoplasm Metastasis
Survival
Recurrence
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

引用此文

Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study. / PSOGI and BIG RENAPE working groups.

於: European Journal of Surgical Oncology, 卷 44, 編號 11, 01.11.2018, p. 1786-1792.

研究成果: 雜誌貢獻文章

@article{67b95bd865ff4a379769770b7c60f6a1,
title = "Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study",
abstract = "Introduction: Peritoneal metastasis (PM) of hepatocellular carcinoma (HCC) without distant spread are rare. The related prognosis is poor without standard treatment available. The role of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly documented. Methods: An international multicentric cohort was constituted by retrospective analysis of 21 patients undergoing CRS/HIPEC for PM of HCC between 1992 and 2016 from 10 reference centers of PSOGI. Data on clinical features, treatment strategies, and survival outcomes were analyzed. Results: The median time interval from the diagnosis of PM to the procedure was 4.5 months. The median peritoneal cancer index was 14. Sixteen patients had complete cytoreduction (CCR0-1). Ten patients had grades 3 to 4 complications. The median duration of follow-up was 52.2 months. The median OS was 46.7 months. The projected 3y-OS and 5y-OS were 88.9 and 49.4{\%} respectively. The median OS for patients with CCR0-1 resection was not reached whereas it was 5.9 months for those with CCR2-3 resection after CRS (p = 0.0005). The median RFS was 26.3 months and projected RFS at 3 years of 36.5 months Three prognostic factors were associated with improved RFS in the univariate analysis: preoperative chemotherapy (p = 0.0156), PCI >15 (p = 0.009), Number of chemotherapy agents used for HIPEC (p = 0.005). Conclusion: CRS/HIPEC is a safe and effective approach in selected patients with PM of HCC. CRS/HIPEC gives the patient a chance for a good relapse free and overall survival and should be considered as an option.",
keywords = "Cytoreductive surgery, Hepatocellular carcinoma, HIPEC, Peritoneal carcinomatosis",
author = "{PSOGI and BIG RENAPE working groups} and Sanket Mehta and Lilian Schwarz and John Spiliotis and Mao-Chih Hsieh and Akaishi, {Eduardo H.} and Diane Goere and Sugarbaker, {Paul H.} and Dario Baratti and Fran{\cc}ois Quenet and Bartlett, {David L.} and Laurent Villeneuve and Vahan Kepenekian and Ahrendt, {S. A.} and Baik, {S. H.} and A. Bhatt and P. Cachin and W. Ceelen and {De Hingh}, I. and {De Simone}, M. and P. Dub{\'e} and Edwards, {R. P.} and J. Franko and L. Gonzalez-Bayon and V. Gushchin and Holtzman, {M. P.} and Hsieh, {M. C.} and D. Kecmanovic and Lee, {K. W.} and K. Lehmann and Levine, {E. A.} and Y. Liu and S. Mehta and Morris, {D. L.} and S. O'Dwyer and E. Orsenigo and Pande, {P. K.} and Park, {E. J.} and Pingpank, {J. F.} and P. Piso and F. Rajan and B. Rau and A. Sardi and L. Sideris and A. Sommariva and Tentes, {A. A.K.} and M. Teo and R. Yarema and Y. Yonemura and R. Younan and Zaveri, {S. S.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.ejso.2018.05.021",
language = "English",
volume = "44",
pages = "1786--1792",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study

AU - PSOGI and BIG RENAPE working groups

AU - Mehta, Sanket

AU - Schwarz, Lilian

AU - Spiliotis, John

AU - Hsieh, Mao-Chih

AU - Akaishi, Eduardo H.

AU - Goere, Diane

AU - Sugarbaker, Paul H.

AU - Baratti, Dario

AU - Quenet, François

AU - Bartlett, David L.

AU - Villeneuve, Laurent

AU - Kepenekian, Vahan

AU - Ahrendt, S. A.

AU - Baik, S. H.

AU - Bhatt, A.

AU - Cachin, P.

AU - Ceelen, W.

AU - De Hingh, I.

AU - De Simone, M.

AU - Dubé, P.

AU - Edwards, R. P.

AU - Franko, J.

AU - Gonzalez-Bayon, L.

AU - Gushchin, V.

AU - Holtzman, M. P.

AU - Hsieh, M. C.

AU - Kecmanovic, D.

AU - Lee, K. W.

AU - Lehmann, K.

AU - Levine, E. A.

AU - Liu, Y.

AU - Mehta, S.

AU - Morris, D. L.

AU - O'Dwyer, S.

AU - Orsenigo, E.

AU - Pande, P. K.

AU - Park, E. J.

AU - Pingpank, J. F.

AU - Piso, P.

AU - Rajan, F.

AU - Rau, B.

AU - Sardi, A.

AU - Sideris, L.

AU - Sommariva, A.

AU - Tentes, A. A.K.

AU - Teo, M.

AU - Yarema, R.

AU - Yonemura, Y.

AU - Younan, R.

AU - Zaveri, S. S.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Introduction: Peritoneal metastasis (PM) of hepatocellular carcinoma (HCC) without distant spread are rare. The related prognosis is poor without standard treatment available. The role of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly documented. Methods: An international multicentric cohort was constituted by retrospective analysis of 21 patients undergoing CRS/HIPEC for PM of HCC between 1992 and 2016 from 10 reference centers of PSOGI. Data on clinical features, treatment strategies, and survival outcomes were analyzed. Results: The median time interval from the diagnosis of PM to the procedure was 4.5 months. The median peritoneal cancer index was 14. Sixteen patients had complete cytoreduction (CCR0-1). Ten patients had grades 3 to 4 complications. The median duration of follow-up was 52.2 months. The median OS was 46.7 months. The projected 3y-OS and 5y-OS were 88.9 and 49.4% respectively. The median OS for patients with CCR0-1 resection was not reached whereas it was 5.9 months for those with CCR2-3 resection after CRS (p = 0.0005). The median RFS was 26.3 months and projected RFS at 3 years of 36.5 months Three prognostic factors were associated with improved RFS in the univariate analysis: preoperative chemotherapy (p = 0.0156), PCI >15 (p = 0.009), Number of chemotherapy agents used for HIPEC (p = 0.005). Conclusion: CRS/HIPEC is a safe and effective approach in selected patients with PM of HCC. CRS/HIPEC gives the patient a chance for a good relapse free and overall survival and should be considered as an option.

AB - Introduction: Peritoneal metastasis (PM) of hepatocellular carcinoma (HCC) without distant spread are rare. The related prognosis is poor without standard treatment available. The role of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly documented. Methods: An international multicentric cohort was constituted by retrospective analysis of 21 patients undergoing CRS/HIPEC for PM of HCC between 1992 and 2016 from 10 reference centers of PSOGI. Data on clinical features, treatment strategies, and survival outcomes were analyzed. Results: The median time interval from the diagnosis of PM to the procedure was 4.5 months. The median peritoneal cancer index was 14. Sixteen patients had complete cytoreduction (CCR0-1). Ten patients had grades 3 to 4 complications. The median duration of follow-up was 52.2 months. The median OS was 46.7 months. The projected 3y-OS and 5y-OS were 88.9 and 49.4% respectively. The median OS for patients with CCR0-1 resection was not reached whereas it was 5.9 months for those with CCR2-3 resection after CRS (p = 0.0005). The median RFS was 26.3 months and projected RFS at 3 years of 36.5 months Three prognostic factors were associated with improved RFS in the univariate analysis: preoperative chemotherapy (p = 0.0156), PCI >15 (p = 0.009), Number of chemotherapy agents used for HIPEC (p = 0.005). Conclusion: CRS/HIPEC is a safe and effective approach in selected patients with PM of HCC. CRS/HIPEC gives the patient a chance for a good relapse free and overall survival and should be considered as an option.

KW - Cytoreductive surgery

KW - Hepatocellular carcinoma

KW - HIPEC

KW - Peritoneal carcinomatosis

UR - http://www.scopus.com/inward/record.url?scp=85048522170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048522170&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2018.05.021

DO - 10.1016/j.ejso.2018.05.021

M3 - Article

C2 - 29885982

AN - SCOPUS:85048522170

VL - 44

SP - 1786

EP - 1792

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 11

ER -